Literature DB >> 24675735

Antigen-specific activation and cytokine-facilitated expansion of naive, human CD8+ T cells.

Matthias Wölfl1, Philip D Greenberg2.   

Abstract

Antigen-specific priming of human, naive T cells has been difficult to assess. Owing to the low initial frequency in the naive cell pool of specific T cell precursors, such an analysis has been obscured by the requirements for repeated stimulations and prolonged culture time. In this protocol, we describe how to evaluate antigen-specific priming of CD8(+) cells 10 d after a single specific stimulation. The assay provides reference conditions, which result in the expansion of a substantial population of antigen-specific T cells from the naive repertoire. Various conditions and modifications during the priming process (e.g., testing new cytokines, co-stimulators and so on) can now be directly compared with the reference conditions. Factors relevant to achieving effective priming include the dendritic cell preparation, the T cell preparation, the cell ratio at the time of priming, the serum source used for the experiment and the timing of addition and concentration of the cytokines used for expansion. This protocol is relevant for human immunology, vaccine biology and drug development.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24675735      PMCID: PMC4312138          DOI: 10.1038/nprot.2014.064

Source DB:  PubMed          Journal:  Nat Protoc        ISSN: 1750-2799            Impact factor:   13.491


  65 in total

1.  Proliferation and differentiation potential of human CD8+ memory T-cell subsets in response to antigen or homeostatic cytokines.

Authors:  Jens Geginat; Antonio Lanzavecchia; Federica Sallusto
Journal:  Blood       Date:  2003-02-06       Impact factor: 22.113

2.  Rapid high efficiency sensitization of CD8+ T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanism.

Authors:  Shuwen Xu; Gary K Koski; Mark Faries; Isabelle Bedrosian; Rosemarie Mick; Markus Maeurer; Martin A Cheever; Peter A Cohen; Brian J Czerniecki
Journal:  J Immunol       Date:  2003-09-01       Impact factor: 5.422

3.  Priming CD8+ T cells with dendritic cells matured using TLR4 and TLR7/8 ligands together enhances generation of CD8+ T cells retaining CD28.

Authors:  Jeffrey S Pufnock; Melinda Cigal; Lisa S Rolczynski; Erica Andersen-Nissen; Mathias Wolfl; M Juliana McElrath; Philip D Greenberg
Journal:  Blood       Date:  2011-04-14       Impact factor: 22.113

Review 4.  Limiting dilution analysis of human T cells: a useful clinical tool.

Authors:  C E Sharrock; E Kaminski; S Man
Journal:  Immunol Today       Date:  1990-08

5.  Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor.

Authors:  Y Kawakami; S Eliyahu; C H Delgado; P F Robbins; L Rivoltini; S L Topalian; T Miki; S A Rosenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

6.  Precursor frequency analysis of human cytolytic T lymphocytes directed against autologous melanoma cells.

Authors:  P G Coulie; M Somville; F Lehmann; P Hainaut; F Brasseur; R Devos; T Boon
Journal:  Int J Cancer       Date:  1992-01-21       Impact factor: 7.396

7.  Organ-specific selection of viral variants during chronic infection.

Authors:  R Ahmed; M B Oldstone
Journal:  J Exp Med       Date:  1988-05-01       Impact factor: 14.307

8.  A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas.

Authors:  P G Coulie; V Brichard; A Van Pel; T Wölfel; J Schneider; C Traversari; S Mattei; E De Plaen; C Lurquin; J P Szikora; J C Renauld; T Boon
Journal:  J Exp Med       Date:  1994-07-01       Impact factor: 14.307

9.  The interleukin 12 p40 gene promoter is primed by interferon gamma in monocytic cells.

Authors:  X Ma; J M Chow; G Gri; G Carra; F Gerosa; S F Wolf; R Dzialo; G Trinchieri
Journal:  J Exp Med       Date:  1996-01-01       Impact factor: 14.307

10.  Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes.

Authors:  Y Kawakami; S Eliyahu; K Sakaguchi; P F Robbins; L Rivoltini; J R Yannelli; E Appella; S A Rosenberg
Journal:  J Exp Med       Date:  1994-07-01       Impact factor: 14.307

View more
  63 in total

1.  Enrichment and Expansion with Nanoscale Artificial Antigen Presenting Cells for Adoptive Immunotherapy.

Authors:  Karlo Perica; Joan Glick Bieler; Christian Schütz; Juan Carlos Varela; Jacqueline Douglass; Andrew Skora; Yen Ling Chiu; Mathias Oelke; Kenneth Kinzler; Shibin Zhou; Bert Vogelstein; Jonathan P Schneck
Journal:  ACS Nano       Date:  2015-07-14       Impact factor: 15.881

Review 2.  AIM Platform: A Novel Nano Artificial Antigen-Presenting Cell-Based Clinical System Designed to Consistently Produce Multi-Antigen-Specific T-Cell Products with Potent and Durable Anti-Tumor Properties.

Authors:  Lauren Suarez; Ruipeng Wang; Scott Carmer; Daniel Bednarik; Han Myint; Kristi Jones; Mathias Oelke
Journal:  Transfus Med Hemother       Date:  2020-11-16       Impact factor: 3.747

3.  Identification and isolation of antigen-specific cytotoxic T lymphocytes with an automated microraft sorting system.

Authors:  Peter J Attayek; Sally A Hunsucker; Christopher E Sims; Nancy L Allbritton; Paul M Armistead
Journal:  Integr Biol (Camb)       Date:  2016-12-05       Impact factor: 2.192

4.  Tracking the Fate and Origin of Clinically Relevant Adoptively Transferred CD8+ T Cells In Vivo.

Authors:  Aude G Chapuis; Cindy Desmarais; Ryan Emerson; Thomas M Schmitt; Kendall Shibuya; Ivy Lai; Felecia Wagener; Jeffrey Chou; Ilana M Roberts; David G Coffey; Edus Warren; Harlan Robbins; Philip D Greenberg; Cassian Yee
Journal:  Sci Immunol       Date:  2017-02-24

5.  Dab2, a negative regulator of DC immunogenicity, is an attractive molecular target for DC-based immunotherapy.

Authors:  Md Selim Ahmed; Se Eun Byeon; Yideul Jeong; Mohammad Alam Miah; Md Salahuddin; Yoon Lee; Sung-Soo Park; Yong-Soo Bae
Journal:  Oncoimmunology       Date:  2015-02-03       Impact factor: 8.110

6.  Proteogenomic-based discovery of minor histocompatibility antigens with suitable features for immunotherapy of hematologic cancers.

Authors:  D P Granados; A Rodenbrock; J-P Laverdure; C Côté; O Caron-Lizotte; C Carli; H Pearson; V Janelle; C Durette; E Bonneil; D C Roy; J-S Delisle; S Lemieux; P Thibault; C Perreault
Journal:  Leukemia       Date:  2016-02-09       Impact factor: 11.528

7.  Molecular Subtype-Specific Immunocompetent Models of High-Grade Urothelial Carcinoma Reveal Differential Neoantigen Expression and Response to Immunotherapy.

Authors:  Ryoichi Saito; Christof C Smith; Takanobu Utsumi; Lisa M Bixby; Jordan Kardos; Sara E Wobker; Kyle G Stewart; Shengjie Chai; Ujjawal Manocha; Kevin M Byrd; Jeffrey S Damrauer; Scott E Williams; Benjamin G Vincent; William Y Kim
Journal:  Cancer Res       Date:  2018-05-21       Impact factor: 12.701

8.  Machine-Learning Prediction of Tumor Antigen Immunogenicity in the Selection of Therapeutic Epitopes.

Authors:  Christof C Smith; Shengjie Chai; Amber R Washington; Samuel J Lee; Elisa Landoni; Kevin Field; Jason Garness; Lisa M Bixby; Sara R Selitsky; Joel S Parker; Barbara Savoldo; Jonathan S Serody; Benjamin G Vincent
Journal:  Cancer Immunol Res       Date:  2019-09-12       Impact factor: 11.151

9.  T Cell Receptor Engineered Lymphocytes for Cancer Therapy.

Authors:  Meagan R Rollins; Ellen J Spartz; Ingunn M Stromnes
Journal:  Curr Protoc Immunol       Date:  2020-06

10.  IL12-mediated sensitizing of T-cell receptor-dependent and -independent tumor cell killing.

Authors:  Matthias Braun; Marie L Ress; Young-Eun Yoo; Claus J Scholz; Matthias Eyrich; Paul G Schlegel; Matthias Wölfl
Journal:  Oncoimmunology       Date:  2016-05-19       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.